Patents by Inventor Dieter Kadereit

Dieter Kadereit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted fused heterocycles as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
    Patent number: 9758520
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: September 12, 2017
    Assignee: SANOFI
    Inventors: Lothar Schwink, Christian Buning, Heiner Glombik, Matthias Gossel, Dieter Kadereit, Nis Halland, Matthias Lohmann, Christoph Pöverlein, Kurt Ritter
  • Dual GLP-1/GIP receptor agonists
    Patent number: 9751926
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 5, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Non-acylated exendin-4 peptide analogues
    Patent number: 9750788
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 5, 2017
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Dual GLP-1/glucagon receptor agonists
    Patent number: 9694053
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: July 4, 2017
    Assignee: SANOFI
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • SUBSTITUTED INDANONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170029405
    Abstract: The present invention relates to indanone compounds. The indanone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of indanone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 2, 2015
    Publication date: February 2, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • SUBSTITUTED FUSED HETEROCYCLES AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170022198
    Abstract: The present invention relates to substituted fused heterocyclic compounds. The substituted fused heterocyclic compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of substituted fused heterocyclic compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS
    Publication number: 20170022260
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: January 26, 2017
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • ISOINDOLINONE COMPOUNDS AS GPR119 MODULATORS FOR THE TREATMENT OF DIABETES, OBESITY, DYSLIPIDEMIA AND RELATED DISORDERS
    Publication number: 20170022182
    Abstract: The present invention relates to isoindolinone compounds. The isoindolinone compounds are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of isoindolinone compounds as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Lothar SCHWINK, Christian BUNING, Heiner GLOMBIK, Matthias GOSSEL, Dieter KADEREIT, Nis HALLAND, Matthias LOHMANN, Christoph PÖVERLEIN, Kurt RITTER
  • Exendin-4 Derivatives as Selective Peptidic Dual GLP-1/Glucagon Receptor Agonists
    Publication number: 20170008944
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: July 8, 2016
    Publication date: January 12, 2017
    Inventors: Martin BOSSART, Andreas EVERS, Torsten HAACK, Katrin LORENZ, Dieter KADEREIT, Michael WAGNER, Bernd HENKEL
  • ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20160272577
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: March 22, 2016
    Publication date: September 22, 2016
    Inventors: Matthias SCHAEFER, Josef PERNERSTORFER, Dieter KADEREIT, Hartmut STROBEL, Werngard CZECHTIZKY, L. Charlie CHEN, Alena SAFAROVA, Aleksandra WEICHSEL, Marcel PATEK
  • 4-[5-(3-CHLORO-PHENOXY)-OXAZOLO[5,4-D]PYRIMIDIN-2-YL]-2,6-DIMETHYL-PHENOXY}-ACETIC ACID FOR USE IN THE PREVENTION OR TREATMENT OF ACUTE KIDNEY INJURY
    Publication number: 20160235756
    Abstract: {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.
    Type: Application
    Filed: October 15, 2014
    Publication date: August 18, 2016
    Applicant: Sanofi
    Inventors: Véronique BRIAND, Sabine GRATZER, Thomas HUEBSCHLE, Philip JANIAK, Dieter KADEREIT, Ashfaq PARKAR, Bruno POIRIER, Matthias SCHAEFER, Paulus WOHLFART
  • EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS
    Publication number: 20160168225
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: June 16, 2016
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
    Patent number: 9328071
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: May 3, 2016
    Assignee: SANOFI
    Inventors: Matthias Schaefer, Josef Pernerstorfer, Dieter Kadereit, Hartmut Strobel, Werngard Czechtizky, L. Charlie Chen, Alena Safarova, Aleksandra Weichsel, Marcel Patek
  • Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring
    Patent number: 9321787
    Abstract: The invention therefore relates to compounds of the formula I in which A, X, Y, R1, R2 and R3 have the given meanings. The compounds of the formula I are suitable, for example, for wound healing.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: April 26, 2016
    Assignee: SANOFI
    Inventors: Dieter Kadereit, Matthias Schaefer, Stephanie Hachtel, Thomas Huebschle, Katrin Hiss
  • DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS DERIVED FROM EXENDIN-4
    Publication number: 20150322128
    Abstract: The present invention relates to dual GLP-1/glucagon receptor agonists and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as for reduction of excess food intake.
    Type: Application
    Filed: April 6, 2015
    Publication date: November 12, 2015
    Inventors: Martin Bossart, Ralf Elvert, Andreas Evers, Torsten Haack, Siegfried Stengelin, Michael Wagner, Dieter Kadereit
  • Exendin-4 Peptide Analogues
    Publication number: 20150166625
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • Dual GLP-1/GIP Receptor Agonists
    Publication number: 20150166627
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • Dual GLP-1/Glucagon Receptor Agonists
    Publication number: 20150164997
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Torsten Haack, Michael Wagner, Bernd Henkel, Siegfried Stengelin, Andreas Evers, Martin Bossart, Dieter Kadereit
  • Exendin-4 Peptide Analogues as Dual GLP-1/GIP Agonists
    Publication number: 20150164995
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin
  • NON-ACYLATED EXENDIN-4 PEPTIDE ANALOGUES
    Publication number: 20150164996
    Abstract: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.
    Type: Application
    Filed: December 12, 2014
    Publication date: June 18, 2015
    Inventors: Dieter Kadereit, Katrin Lorenz, Andreas Evers, Torsten Haack, Michael Wagner, Bernd Henkel, Martin Lorenz, Siegfried Stengelin